Thank you for the submission of your research manuscript to the EMBO Journal. We have now received a complete set of referee reports. You will see that all four referees are supportive of this work, noting that the dataset is interesting, novel and well executed. Nevertheless, all the referees raise overlapping experimental and textural issues, which have to be addressed by substantial revision. The issues we highlight are not further reaching points, but important to ensure publication of a robust, well-controlled and well-developed paper.
Given these evaluations, I would like to give you the opportunity to revise your manuscript, with the understanding that the referee concerns must be fully addressed by additional experimentation where necessary, and that acceptance of the manuscript is likely to entail validation with a subset of the referees. In our view addition of epigenetic regulation of Chd4 promoter in fig 4B is a further reaching point which is not essential for publication. In fig 6 the referee suggests to add the reciprocal experiment: does Ezh2 depletion affect Chd4 binding? We encourage addressing this very constructive suggestion, but failure to do so will not preclude publication. The three requests for controls have to be addressed. ref 3 requests to examine the role of Chd4 in Ezh2 recruitment and H3K27 me3 to GFAP promoter in NPCs at E11.5 & 16.5 and to modify the data presentation.
ref 4 suggests to simplify the presentation by removing the less novel data. We suggest this is done by moving relevant data to the supplementary information section. In particular, point 5 regarding fig 4 needs to be addressed experimentally. Point 6 recommends rescuing Chd4 expression at later stages in vivo, which would indeed be an excellent addition that should be considered, but we are open to discuss this experiment if it proves technically challenging. The discrepancy noted in fig 2A needs to be addressed. Note that the referee requests addition of a number of controls.
Please note that revised manuscripts should be submitted within three months; if your revision are likely to take longer, please discuss the matter with us at this time. If the conceptual advance of the study is not further eroded by publications that have appeared in the meantime, we can grant an extension of the revision period. While studies published during the revision period are not taken into account in terms of conceptual advance evaluation, we require that you contact us immediately so that we can discuss a constructive way forward.
When submitting your revised manuscript, please include a Microsoft Word file (or equivalent) of the manuscript text, editable TIFF or EPS-formatted figure files, a separate PDF file of any Supplementary information (in its final format) and a letter detailing your responses to the referee comments.
As part of the EMBO publication's Transparent Editorial Process, EMBO Journal publishes online a Review Process File to accompany accepted manuscripts. This File will be published in conjunction with your paper and will include the referee reports, your point-by-point response and all pertinent correspondence relating to the manuscript.
I look forward to seeing a revised form of your manuscript in due course.
___________________________ REFEREE COMMENTS

Referee #1
Sparmann et al describe a function for the PRC2 subunit Ezh2 and NuRD subunit Chd4 to repress astrocyte differentiation in neural progenitor cells (NPCs). The authors find that this collaboration between Ezh2 and Chd4 is independent of the NuRD complex and does not extend to all polycomb target genes. Overexpression of Ezh2 in NPCs inhibits gliogenesis, while knockdown of Ezh2 or Chd4 promotes premature expression of astrocyte markers. Focusing on the astrocyte marker GFAP, both Ezh2 and Chd4 are enriched throughout the promoter and gene body, and knockdown of Chd4 results in loss of Ezh2 binding, providing a mechanistic link between Chd4 and Ezh2 in regulation of gliogenesis. Although Chd4 promotes Ezh2-mediated repression of gliogenesis, this collaboration does not extend to Ezh2's function at later developmental stages to inhibit neurogenesis. Combined with previous data, these results show that Ezh2 functions dynamically during different phases of neural development, preventing premature glial differentiation during neurogenesis and later restriction of neurogenesis during glial differentiation.
In general, the experiments are well designed and (with a few exceptions) the data are convincing. The findings that Ezh2 silences different differentiation programs during different phases of development and that it functions with Chd4 independently of NuRD are interesting and represent a significant advance. However, the data supporting the latter point are based on a single western blot and require further support. In addition, there were a number of additional points where further clarification or modifications would improve the manuscript.
Specific points: 1) Much of the discussion regarding the timing of the developmental potential of NPCs and the appearance of differentiation markers in vivo is imprecise and confusing. Additional explanations throughout the manuscript of when specific markers appear and when NPCs become competent (and cease to be competent) for specific modes of differentiation would facilitate interpretation of the data. As one example, the authors observe "premature gliogenesis in the cerebral cortex of E16.5 mouse embryos" in Nestin-Cre Ezh2-Flox mice, but since E16.5 is a time at which NPCs are competent for gliogenesis, it is not completely clear why some GFAP-positive cells would not be expected to be present.
2) In Figure 2A , control and bioEzh2 expressing cells express similar levels of total (tagged + untagged) Ezh2 during differentiation. How then can the reduction of neuronal and glial differentiation potential observed in bioEzh2 cells (Fig. 2B-C ) be due to differences in Ezh2 activity? The authors should explain this point.
3) Does Chd4 KD affect bioEzh2 levels? This data might be present in Fig. S2 , but there seems to have been a mixup - Figure S2 has been replaced with a second copy of Figure 2 in the manuscript. Figure S4B is presented as the percentage of marker-positive cells that express either Tuj1 or GFAP. In these experiments, does Ezh2 KD not only reduce astrocyte differentiation in E16.5 NPCs, but also simultaneously increase neuronal differentiation, or do overall levels of Tuj1-positive cells remain unchanged and merely increase in proportion to the lower levels of GFAPpositive cells? 5) Similarly, in Fig. 3B , the proportion of Tuj1-positive cells is decreased, while GFAP-positive cells are increased. Is the overall number of Tuj1-positive cells reduced in this experiment, or only the proportion of Tuj1-positive cells relative to GFAP-positive cells? It was difficult to tell from the immunofluorescence image in 3A. The raw number of cells exhibiting each marker would be useful to understand whether the NPC differentiation program has shifted from neurogenesis to gliogenesis, or if gliogenesis is increased independently of neurogenesis.
4)
6) The data showing enrichment of H3K9me3 over IgG ChIP for every region of the GFAP locus (Fig. 6G) is not particularly meaningful and adds little to the manuscript. In fact, K9me3 enrichment at the GFAP promoter (primer pair D) is similar to the IGR control locus, so there is no evidence that K9me3 is enriched at GFAP relative to any other location. Either the authors should provide evidence that K9me3 has some function at this locus (e.g., KD Suv39h1 and Suv39h2 and examine Chd4 binding) or they should remove this data. Fig. 7A : The authors show that Chd4 KD results in reduced H3K27me3 levels at GFAP. Brian Hendrich's lab showed that NuRD complex deacetylates H3K27 in ES cells, which is necessary for Ezh2-mediated H3K27 methylation (Reynolds et al, 2011) . Is the loss of H3K27me3 upon Chd4 KD in NPCs accompanied by a concomitant increase in H3K27Ac? If this effect of Chd4 KD is NuRDindependent, one might expect H3K27Ac levels to be low with or without Chd4 KD.
7)
8) The data that Mbd3/Hdac1 KDs do not affect Chd4-mediated silencing of gliogenic genes (Fig.  S7) are not terribly convincing. This conclusion is based on one western blot of GFAP, which shows that GFAP levels are increased a few fold upon Chd4 KD. However, the background (no Dox) GFAP levels in the shChd4 cells are higher than in any of the other lines (pRS, pRS-Hdac1, pRSMbd3), so it's not clear that there is no increase in the Mbd3 or Hdac1 KD cells. This could be determined quantitatively by RT-qPCR for all three KDs. Furthermore, since the NuRD-independent function of Chd4 in PRC2 repression is one of the more interesting points in the paper, additional genes (such as those tested in Fig. 7E ) could be examined by RT-qPCR to convincingly show that NURD complex is not required for Chd4's function in regulation of astrocyte differentiation.
Referee #2
In this manuscript Sparmann and coworkers report that Chd4, a novel substoichiometric component of the PRC2 complex is required for neocortical development and Neuronal Progenitor Cells (NPC) commitment. The authors show that at E11.5, when NPC are not yet committed to astrocyte differentiation, Ezh2 blocks precocious glial differentiation, whereas at E16.5 Ezh2 promotes astrocyte differentiation, repressing Neurogenin 1. These results confirm previous findings (Pereira et al., and Hirabayashi et al.) The main finding of the paper is the association of Chd4, component of the NuRD complex, with PRC2 in NPC. Indeed Chd4 KD induces precocious glial differentiation in E11.5 derived NPC and in early developing cerebral cortex. The inhibition of precocious glial differentiation is due to the repression of the GFAP promoter. Chd4 seems to be necessary for the binding of PRC2 component Ezh2 on the GFAP promoter and for the deposition of the repressive mark H3K27me3. No effects of Chd4 KD were observed in E16.5 NPC. This is in agreement with the strong decrease of Chd4 protein levels occurring at this stage compared to earlier developmental stages This manuscript has been revised extensively prior to its submission in EMBO Journal. I find the quality of the experiments presented here appropriate and the impact of conclusions highly interesting. I do have a few concerns/questions that should be addressed prior to publication. 1. Include western blot for MBD3, MTA1 and MTA3 in figure 1E . 2. In figure 4B the authors show that Chd4 expression levels is dramatically decreased in NPC at E16.5 compared to E14.5. Is this due to epigenetic regulation of Chd4 promoter? Is this regulation eventually mediated by PRCs? 3. In figure 5 , the authors claim that Chd4 depletion resulted in a 2-fold increase of GFAP positive cells in ventricular zone of embryonic cerebral cortex. This effect resembles Ezh2 KD. The authors should show whether Chd4 KD affects Ezh2 expression. 4. Depletion of Chd4 affects EZH2 occupancy at GFAP promoter. Does deletion of Ezh2 affects Chd4 binding? In other words are both necessary for reciprocal stable occupancy? 5. The authors reported that MBD3 KD doesn't induce derepression of GFAP promoter. Is Ezh2 binding and/or H3K27me3 marks nevertheless affected?
Minor points: -In figure 1B the authors should include the expression of Sox2 by immunostaining upon Ezh2 over-expression in NPC.
-Analysis of the expression of others PRC1/2 components upon NPC differentiation should be included in figure 2A .
Referee #3
This study shows an interaction between Ezh2 and Chd4 and attempts to clarify the mechanism underlying the diversity of PcG functions in relation to glial development. The authors propose that Chd4 plays an important role in recruiting PcG complexes, but only to a subset of target loci involved in astrocyte differentiation in a temporally specific manner. Thus, Chd4 may distinguish between divergent functions of Ezh2 in suppressing neurogenesis versus gliogenesis. Regulation of target specificity is a very important issue in understanding PcG-mediated regulation of transcription and cell fate. However, there are some issues that remain to be addressed in order to substantiate the authors' conclusions.
Specific points 1. Since the role of Chd4 in recruiting PcG proteins to specific targets (in a stage dependent manner) is a central finding of this study, the role of Chd4 in the recruitment of Ezh2 and/or H3K27me3 to the GFAP promoter should be examined in NPCs at E11.5 and E16.5. 2. Temporal action of Ezh2 is an important part of this study. Therefore, I would suggest that the authors include the results of Fig. S4 in the main figures (such as in Fig. 3 ). 3. Some experimental conditions are not properly described. The authors should clarify whether "diff" means a neuronal or astrocyte differentiation condition in each figure. The % of marker positive cells compared to such cells in BirA control experiments is not an appropriate way to indicate a differentiation phenotype. Instead, the authors should show the raw number (% of marker positive cells among all cells) in both control and experimental conditions.
Referee #4
Sparmann et al. investigated the function of the PcG protein Ezh2 and uncovered a possible cofactor Chd4 that, intriguingly, seems to function in gliogenesis rather than neurogenesis. The authors did a thorough job of addressing the reviewers comments. Importantly, they have added the in vivo evidence for Chd4 function, which was critical. In this study they performed in vitro analyses using neural progenitor cells (NPCs) derived from mouse embryonic stem cells (ESCs), primary tissue and from wild type or Dox-inducible shRNA targeting Ezh2 transgenic mice (ArtEzh2tetKD). In vivo evidence was obtained using Nestin-CRE mediated Ezh2 conditional knockout mice and in utero electroporation with Chd4 shRNA. They convincingly demonstrated the interaction between Ezh2 and Chd4 using BirA-mediated biotinylation and mass spectrometric analysis. Then they showed 1. Chd4 is needed for Ezh2-mediated inhibition of astrogenesis but not neurogenesis in vitro, 2. Chd4 knockdown activated gliogenesis both in vivo and in vitro and 3. Chd4 recruits Ezh2 to the GFAP genomic loci to complete the H3K27 trimethylation using CHIP assay. In summary, this study identifies Chd4 as a novel regulator of gliogenesis but not neurogenesis, through recruiting Ezh2 to GFAP genomic loci. It is an interesting example of how the epigenetic machinery regulates cell lineage, and moreover that a certain co-factor may specifically participate in a restricted cell lineage. Overall there is much novelty here and this is an interesting and important study.
However, I would recommend some re-organization to simplify the manuscript and to emphasize the novel work on Chd4. There are several unnecessary experiments shown that focus on Ezh2 loss, which was already well-reported by Pereira et al. Hence, I would suggest the following:
1. I would recommend that the authors remove the work reported in Fig 3: the work on primary mouse NPCs from WT or Dox-inducible shRNA targeting Ezh2 transgenic mice (ArtEzh2tetKD), and the analysis of Nestin-CRE mediated Ezh2 conditional knockout mice, as this repeats what is in the literature and need not be shown again.
2. Explain when they are using mouse ESCs-NPCs and when they are using primary NPCs -in general, clearer labels on the figures would be very helpful.
3. In Fig2A of the differentiated condition, between BirA ctrl and BirA+bioEzh2 groups, it is hard to tell that total Ezh2 protein level (endo Ezh2 and bioEzh2) in the BirA+bioEzh2 group is higher than the Ezh2 protein in the BirA control group. If the authors can provide a quantified graph of Ezh2 protein level change among groups, it would be very helpful.
4. Note that on page 11 paragraph two, where they discuss the premature gliogenesis observed in the Nestin-mediated Ezh2 conditional knockout mice, if they chose to retain this work they should note that similar results were reported by Pereira et al., (2010) . Also, the GFAP signal is not convincing in Fig 3D, there appears to be a lot of vessel background. In contrast, the pictures in Pereira et al are really clear. The authors need to provide more convincing GFAP staining.
5. The novel part of this study is the function of Chd4 in regulating gliogenesis. The in vivo evidence the authors provided is in utero electroporation using Chd4 shRNA at embryonic day 13.5 (E13.5), which is a peak stage of neurogenesis in the developing cortex. They showed that there was a slight increase in GFAP+ cells after Chd4 knockdown (Fig 5A,5B ), indicating that Chd4 may inhibit gliogenesis in the neurogenic phase. However, it is surprising to see GFAP+ cells down in the ventricular zone (VZ). Mature astrocytes, like mature neurons, rapidly move out and migrate into the overlying layers, as shown by Pereira et al. and others. The authors should examine if there is an increase of GFAP+ cells in electroporated cells in the upper regions eg the cortical plate (CP) region after Chd4 knockdown (KD). Moreover, given the robust increase in GFAP+ cells after Chd4 KD in E11.5 NPC cultures (Fig. 4C,4D ), I would expect a higher increase in GFAP+ cells after knocking down Chd4 in vivo. The authors should discuss why GFAP+ cells production was weak in vivo after Chd4 KD.
6. Fig 4B shows that Chd4 level reduces dramatically in NPCs derived from later stages of cortical development. This may explain why knocking down Chd4 inhibited gliogenesis during the neurogenic phase (Fig 4C) , but had little impact on gliogenesis during the gliogenic phase (supplementary Fig5 B, C) . Hence, I recommend that the authors consider over-expressing Chd4 at E15/E16 by in utero electroporation, to examine if gliogenesis is delayed or not.
7. In Fig 4C,4D , the authors showed that Chd4 KD led to an increase in GFAP+ cells from NPCs derived from E11.5 cortex. They should check the percentage of Tuj1+ cells in these conditions as well. If there is no difference in the percentage of Tuj1+ cells, it would further solidify the conclusion that Chd4 has a specific impact on gliogenesis but not on neurogenesis. 10. Page14, in the sentence "it is interesting to 'not' that we also detect significant enrichment" , I assume that it should be "note". Response to the referees
We would like to thank all four reviewers for the evaluation of our study as well as their constructive criticism, which allowed us to strengthen and clarify our conclusions. Below we respond in detail to each comment and discuss how the raised concerns were incorporated in the revised manuscript. We have clarify the text accordingly. In rodents, the neurogenic-to-gliogenic switch normally takes place during neo-cortical development between E17.5 and E19.5 (Kriegstein and Alvarez-Buylla, 2009; Marshall et al., 2003) . Interestingly, this timed genesis also occurs in culture. Primary E10-12 cortical precursors generate only neurons for the first few days in culture, followed by the subsequent differentiation into astrocytes. NPCs isolated on E16.5 -just prior to their acquisition of glial competence -will gain the full potential to differentiate into astrocytes during the three-day culture period following isolation. In-vivo, astrocytes usually appear only at around E18, with their numbers peaking in the neonatal period (Quian et al., 2000) . Therefore, the presence of GFAP-positive cells at E16.5 in-vivo is not necessarily to be expected.
Referee #1
Sparmann et al describe a function for the PRC2 subunit Ezh2 and NuRD subunit Chd4 to repress astrocyte differentiation in neural progenitor cells (NPCs
2) In Figure 2A, control and bioEzh2 expressing cells express similar levels of total (tagged + untagged) Ezh2 during differentiation. How then can the reduction of neuronal and glial differentiation potential observed in bioEzh2 cells (Fig. 2B-C) be due to differences in Ezh2 activity? The authors should explain this point.
We have now quantified the respective immuno-reactive bands using the Image J software and do find a slight elevation of total Ezh2 levels in cells expressing the exogenous transgene. This effect is admittedly small. Due to the low expression of Ezh2 in differentiated cells, it might nevertheless be sufficient to cause the observed effects.
3) Does Chd4 KD affect bioEzh2 levels? This data might be present in Fig. S2, but there seems to have been a mixup -Figure S2 has been replaced with a second copy of Figure 2 in the manuscript.
We apologize for this mistake and the initial omission of these important data. Depletion of Chd4 does not affect bioEzh2 levels -we have now added the relevant western blots in Figure 2F and Supplemental Figure 2E .
4) Figure S4B is presented as the percentage of marker-positive cells that express either Tuj1 or GFAP. In these experiments, does Ezh2 KD not only reduce astrocyte differentiation in E16.5 NPCs, but also simultaneously increase neuronal differentiation, or do overall levels of Tuj1-positive cells remain unchanged and merely increase in proportion to the lower levels of GFAP-positive cells?
We now present the data as "% of marker positive cells" in relation to the total number of cells. This clarifies that Ezh2 KD indeed also causes an increase in neuronal differentiation, as has previously been shown by Hirabayashi et al., 2009 . According to the suggestion of reviewer #3, this data has now been moved to Figure 3A and B.
5) Similarly, in Fig. 3B, the proportion of Tuj1-positive cells is decreased, while GFAP-positive cells are increased. Is the overall number of Tuj1-positive cells reduced in this experiment, or only the proportion of Tuj1-positive cells relative to GFAP-positive cells? It was difficult to tell from the immunofluorescence image in 3A. The raw number of cells exhibiting each marker would be useful to understand whether the NPC differentiation program has shifted from neurogenesis to gliogenesis, or if gliogenesis is increased independently of neurogenesis.
We have now expressed these data as the % of marker positive cells among all cells. The quantification is presented in Figure 3E , and indicates that Ezh2 KD triggers a shift from neurogenesis to gliogenesis.
6) The data showing enrichment of H3K9me3 over IgG ChIP for every region of the GFAP locus (Fig. 6G) is not particularly meaningful and adds little to the manuscript. In fact, K9me3 enrichment at the GFAP promoter (primer pair D) is similar to the IGR control locus, so there is no evidence that K9me3 is enriched at GFAP relative to any other location. Either the authors should provide evidence that K9me3 has some function at this locus (e.g., KD Suv39h1 and Suv39h2 and examine Chd4 binding) or they should remove this data.
We agree with the reviewer regarding the lack of relevance of these data without a functional validation of their significance. We felt that the analysis of the role of H3K9-trimethylation for Chd4 recruitment to the GFAP locus, albeit interesting, is a further reaching point not immediately pertinent to the central conclusions of our study, and have therefore removed the data as suggested. Fig. 7A We appreciate this suggestion and recognize the relevance to functionally separate the two distinct mechanisms of cooperation between Chd4 and PRC2. However, measuring the level of H3K27 acetylation at the GFAP locus after Chd4 KD does not necessarily resolve the issue. Even if H3K27Ac levels increase after depletion of Chd4, this could be due to the enhanced availability of the H3K27 residue for acetylation after the removal of the methyl mark. Thus, this result would not explicitly demonstrate that Ezh2-mediated H3K27-trimethylation at the GFAP locus requires NuRD-dependent H3K27 deactetylation. On the other hand, consistently low levels of H3K27Ac before and after Chd4 KD, although indicative, do not rule out the involvement of the NuRD complex. We find that the data we added in response to comment 8) (see below) more directly address the issue of a NuRD-independent function of Chd4 during Polycomb silencing.
7)
8) The data that Mbd3/Hdac1 KDs do not affect Chd4-mediated silencing of gliogenic genes (Fig. S7) are not terribly convincing. This conclusion is based on one western blot of GFAP, which shows that GFAP levels are increased a few fold upon Chd4 KD. However, the background (no Dox) GFAP levels in the shChd4 cells are higher than in any of the other lines (pRS, pRS-Hdac1, pRSMbd3), so it's not clear that there is no increase in the Mbd3 or Hdac1 KD cells. This could be determined quantitatively by RT-qPCR for all three KDs. Furthermore, since the NuRD-independent function of Chd4 in PRC2 repression is one of the more interesting points in the paper, additional genes (such as those tested in Fig. 7E) could be examined by RT-qPCR to convincingly show that NURD complex is not required for Chd4's function in regulation of astrocyte differentiation.
We included the requested RT-qPCR analysis of GFAP as well as of the additional genes analyzed in Figure 7E upon knock-down of HDAC1 and MBD3 in Supplemental Figure 7B and C. The observed lack of derepression of any of these Chd4-dependent Polycomb targets strengthens our initial conclusion that the effects of Chd4 on Polycomb-mediated gene silencing during astrocyte differentiation are likely distinct from its function as part of the NuRD complex. Furthermore, we included an additional ChIP analysis after MBD3 KD that demonstrates that H3K27-trimethylation at the GFAP locus is not dependent on NuRD complex integrity. (Pereira et al., and Hirabayashi et al.) The main finding of the paper is the association of Chd4, component of the NuRD complex, with PRC2 in NPC. Indeed Chd4 KD induces MBD3, MTA1 and MTA3 in figure 1E .
Referee #2
In this manuscript Sparmann and coworkers report that Chd4, a novel substoichiometric component of the PRC2 complex is required for neocortical development and Neuronal Progenitor Cells (NPC) commitment. The authors show that at E11.5, when NPC are not yet committed to astrocyte differentiation, Ezh2 blocks precocious glial differentiation, whereas at E16.5 Ezh2 promotes astrocyte differentiation, repressing Neurogenin 1. These results confirm previous findings
We have included a western blot for MBD3 in Figure 1E . Since MBD3 is an essential component of NuRD necessary for complex stability, we believe that this significantly strengthens our conclusion that the interaction between Chd4 and PRC2 does not involve integral NuRD members. figure 4B the authors show that Chd4 expression levels is dramatically decreased in NPC at E16.5 compared to E14.5. Is this due to epigenetic regulation of Chd4 promoter? Is this regulation eventually mediated by PRCs?
In
The regulation of Chd4 expression during cortical development is certainly a very interesting question and could well be dependent on epigenetic mechanisms. However, we find that this analysis extends beyond the scope of our current manuscript and should be comprehensively addressed by future studies.
In figure 5, the authors claim that Chd4 depletion resulted in a 2-fold increase of GFAP positive cells in ventricular zone of embryonic cerebral cortex. This effect resembles Ezh2 KD. The authors should show whether Chd4 KD affects Ezh2 expression.
Due to the difficulty of quantitatively evaluating immune-fluorescent signals, we have not attempted IHC staining for Ezh2 on cortical sections. However, we do show by western blot analysis of NPC lysates that Chd4 KD does not affect Ezh2 levels.
Depletion of Chd4 affects EZH2 occupancy at GFAP promoter. Does deletion of Ezh2 affects Chd4 binding? In other words are both necessary for reciprocal stable occupancy?
We agree with the reviewer that it is important to further investigate the mechanism governing recruitment of both Chd4 and Ezh2 to the GFAP locus and that it would be interesting to determine if Ezh2 is required for the stable association of Chd4 to the GFAP promoter. However, this study mainly aims to establish that the Ezh2-mediated inhibition of GFAP expression requires Chd4. By demonstrating that depletion of Chd4 affects Ezh2 occupancy at the GFAP locus, we have provided evidence for this claim. We find that the analysis of a possible reverse dependence does not necessarily provide considerable further mechanistic insight. We have therefore decided to omit this experiment in our revision.
The authors reported that MBD3 KD doesn't induce derepression of GFAP promoter. Is Ezh2 binding and/or H3K27me3 marks nevertheless affected?
We included an additional ChIP analysis of the GFAP promoter after MBD3 KD in Supplemental Figure 7D to demonstrate that H3K27-trimethylation of the locus is not affected by depletion of MBD3.
Minor points: -In figure 1B the authors should include the expression of Sox2 by immunostaining upon Ezh2 overexpression in NPC.
We have now included the immune-cytochemical analysis for Sox2 in Figure 1B .
We have included a western blot for Suz12 in Figure 2A . We agree with the reviewer about the importance of the suggested experiment. Unfortunately, it is technically not feasible due to the low number of NPCs that can be isolated from E11.5 embryos. In order to have sufficient material to conduct a ChIP analysis, the cells would have to be expanded in culture for a significant amount of time. During this culture period, E11.5 NPCs would progressively gain gliogenic competence. This would preclude the analysis of the role of Chd4 in Ezh2-mediated repression of the GFAP locus, as this only occurs during the early neurogenic period. Therefore, we had to resort to in-vitro derived NPCs in order to conduct this experiment. Fig. S4 in the main figures (such as in Fig. 3) .
Temporal action of Ezh2 is an important part of this study. Therefore, I would suggest that the authors include the results of
We have now included the data previously presented in Supplemental Figure 4A -C in Figure 3 . We agree that the study by Pereira et al., 2010 demonstrates that deletion of Ezh2 before the onset of neurogenesis causes precocious astrocyte differentiation in-vivo. We have therefore removed our analysis of the Nestin-Cre Ezh2 fl/fl mouse model presented in Figure 3D . However, Pereira et al. focus predominantly on the altered rate of cortical neurogenesis and show that early cortex-specific deletion of Ezh2 alters the balance between self-renewal and differentiation in radial glial cells. Although the authors discuss the apparently contrasting findings of Hirabayashi et al., they do not experimentally address the highly temporal effects of Ezh2 deletion. We feel that our data using primary NPCs isolated at different time points from the same ArtEzh2tetKD mouse model allows us to clearly demonstrate that Ezh2 holds opposing functions in different phases of NPC differentiation. We have therefore decided to retain the data presented in Figure 3A -C, and, based on a suggestion of reviewer #3, combined it with the analysis previously shown in Supplemental Figure 4A-C. repression. Therefore, we were concerned that the suggested experiment would not necessarily be sufficiently conclusive to warrant the considerable time and effort required to conduct it. Fig 4C,4D, We included this analysis in Figure 4E and F. Indeed, we do not observe an effect of Chd4 KD on neuronal differentiation. We apologize for the poor image quality, which is most likely due to .pdf conversion and size reduction of the Figures. We have included DAPI staining whenever the overlay did not interfere with the visibility of the additional fluorescent signals imaged in the photomicrographs. For example in Figure 4C and E, the DAPI signal impedes the presentation of the relatively weak GFP signal, which is crucial to identify cells infected with the lentivirus expressing the inducible short hairpin constructs. We consistently observed a dramatic decrease in Ezh2 protein during both neuronal or astroglial differentiation of either primary or in-vitro derived NPCs in culture. In addition, Pereira et al. reported that Ezh2 levels in cortical progenitor cells decrease over the period of neurogenesis invivo. As it was not deemed essential by this reviewer, we have now removed former Figure 3D .
Some experimental conditions
In
The image quality of immunostaining
Page14, in the sentence "it is interesting to 'not' that we also detect significant enrichment", I assume that it should be "note".
That is correct. Incidentally, we have deleted this sentence because we removed the associated data based on a suggestion of referee #1.
Thank you for your patience while we re-reviewed your revised manuscript. As you will see from the reports of referees 1 and 4 below, both referees are now in principle positive about its publication in EMBO Journal. Note, however, that referee 4 is not satisfied with your answer to his/her point 5. We would require that the discussion is adapted to reflect the referee's point.
